Envision Report

Published January 12, 2018

North America Cancer Biomarkers Market – Size, Outlook, Trends and Forecasts (2018 – 2024)

Request Free Sample Report!

Cancer biomarkers are used to trace and indicate the biological state of a tumour and thus analyse diagnostic and prognostic stages of cancer. Cancer biomarkers are into various fields such as drug discovery, development, personalised medicine, and diagnostics. Diagnostics is the principal revenue-generating application of market relating to factors such as increasing growth of biomarker-based oncology tests with higher sensitivity.

North America Cancer Biomarkers Market Segments Size & growth:

The market is valued at USD 3.996 Billion in 2017 and is expected to reach USD 7.328 Billion by 2024 at a CAGR of 10.11%. The major Key factors influencing the market growth are an increase in awareness among patients and healthcare professionals about the necessity of early diagnostics of malignance’s and rising demand for personalised medicine is anticipated to provide the market with significant growth.

North America Cancer Biomarkers Market Segments Share:

Cancer type segments cancer biomarkers market into breast cancer, lung cancer, colorectal cancer, melanoma; prostate, thyroid etc. over all these breast cancers is holding the most significant share in the market due to the prevalence of breast cancer and awareness about the diagnosis. The cancer biomarkers market is segmented by type, disease, service, application, and technologies. Of the kind, the market is categorised into protein biomarkers, genetic biomarkers, cell biomarkers, viral biomarkers, carbohydrate biomarkers. By disease, the market is classified into prostate cancer, lung cancer, breast cancer, colorectal cancer and cervical cancer. By service, the market is categorised into sample preparation, assay development, biomarkers validation and testing. By application, the market is classified into risk assessment, development of molecular diagnostics, disease diagnostics, drug discovery, and development. By technologies, the market is categorised into Omics technologies, imaging technologies, cytogenetics, bioinformatics and IVD multivariate index assays. Geographically, North America is the dominant region globally, and the United States is the primary contributor. Asia-Pacific is expected to be the fastest growing regional market due to the prevalence of cancer in that region.

North America Cancer Biomarkers Market Trends:

  • Abbott got new FDA labelling for some of its MRI active devices and announced the acquisition of st.jude medical, Inc. this transaction provides Abbott with expanded opportunities for future growth.
  • Agilent technologies and multiplicon N.V signed an agreement under which Agilent will acquire multiplicon, a leading European diagnostics company.

North America Cancer Biomarkers Market Research Report Includes:

An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.

To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.

Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year

Identifying DROC in the current market and their impact in altering the market dynamics.

Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial study with significant competitors.

Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.

The principal market players are:

  • Affymetrix Inc
  • Illumina Inc
  • Abbott Laboratories
  • Roche Diagnostics Corp.
  • Agilent Technologies

1. Introduction

1.1.   Executive Summary

1.2.   Market Definition

1.3.   The scope of the Study

2. Research Methodology

2.1.   Secondary Research

2.2.   Primary Research

2.3.   Analytics Tools & Model

2.4.   Economic Indicators

2.4.1.Base Year, Base Currency & Forecasting Period

2.5. Expert Validation

2.6. Study Timeline

3. Market Analysis

3.1.   Industry Value Chain Analysis

3.2.   Porter’s Five Force Analysis

3.2.1 Bargaining Power of Suppliers

3.2.2 Bargaining Power of Buyers

3.2.3 Threat of Substitutes

3.2.4 Threat of New Entrants

3.2.5 Industry Rivalry (Competitive Environment)

3.3. PESTLE Analysis

3.3.1 Political

3.3.2 Economical

3.3.3 Social

3.3.4 Technological

3.3.5 Legal

3.3.6 Environmental

3.4. SWOT Analysis

3.4.1 Strengths

3.4.2 Weakness

3.4.3 Opportunities

3.4.4 Threats

3.4.5 Y-O-Y Analysis

4. Market Dynamics

4.1. Drivers

4.1.1 Increase in corporate partnerships to accelerate development and commercialise of regenerative medicine.

4.1.2 Increase in global healthcare expenditure.

4.1.3 Rapid growth in ageing population.

4.1.4. Prevalence of chronic diseases and genetic disorders.

4.2. Restraints

4.2.1 Cost of treatment.

4.2.2 Complex regeneration process.

4.2.3. Lack of guidelines.

4.2.4. Ethical concerns with the use of embryonic stem cell for research and development.

4.3. Opportunities

4.3.1. Strong product pipeline.

4.3.2. The great demand for organ transplantation.

4.4. Challenges

4.4.1 Stringent regulatory policies about stem cell technologies.

5. North America Cancer Biomarkers Market – By Disease

5.1 Introduction

5.2 Prostate cancer

5.3 Lung cancer

5.4 Cervical cancer

5.5 Colorectal cancer

5.6 Breast cancer

6. North America Cancer Biomarkers Market – By Application

6.1 Introduction

6.2 Risk assessment

6.3 Disease diagnostics

6.4 Development of molecular diagnostics

6.5 Drug formation

7. North America Cancer Biomarkers Market – By Service

7.1 Introduction

7.2 Sample preparation

7.3 Assay development

7.4 Biomarkers validation and testing

8. North America Cancer Biomarkers Market – By Type

8.1 Introduction

8.2 Protein biomarkers

8.3 Cell biomarkers

8.4 Genetic biomarkers

8.5 Carbohydrate biomarkers

8.6 Viral biomarkers

8.7 Others

9. North America Cancer Biomarkers Market – By Technology

9.1 Introduction

9.2 Omics technology

9.3 Cytogenetics

9.4 Imaging technologies

9.5 Immuno Assays

9.6 Bioinformatics

9.7 IVD multivariate

9.8 Index assays

10. North America Cancer Biomarkers Market – By Country

10.1 North America

10.1.1 Introduction

10.1.2 United States

10.1.3 Canada

10.1.4 Mexico

10.1.5 Others

11. North America Cancer Biomarkers Market – Company Profiles

11.1 Affymetrix Inc

11.2 Agendia BV

11.3 Abbott Laboratories

11.4 Roche Diagnostics Corp.

11.5 Agilent Technologies

11.6 Astex Pharmaceuticals

11.7 Illumina Inc

11.8 Diadexus Inc

11.9 Qiagen N.V

11.10 Aureon Biosciences Inc

11.11 Becton, Dickinson and Company

11.12 Beckman Coulter Inc

11.13 Clarient Inc

11.14 Astellas Pharma US Inc

12. North America Cancer Biomarkers Market – Competitive Landscape

12.1 Market Share Analysis

12.2 Strategies Adopted by top companies

12.3 Merges, Acquisitions, Collaborations & Agreements

13. Market Insights

13.1 Industry Experts Insights

13.2 Analysts Opinions

13.3 Investment Opportunities

14. Appendix

14.1 List of tables

14.2 List of figures

  • Competitive Analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors.
  • Monitoring the external and internal factors which affect the market dynamics with the aid of PESTLE analysis.
  • The Regional and Global Variety is taken care of in the report.
  • Year on Year basis generation of revenue is studied.
  • Porter's Five Forces analyze the intensity of competition in an industry and its profitability level.
  • The overview and the sustainability of the market are analyzed through SWOT.
  • DROC is recognized in the current market scenario and see how its effect on market dynamics.
  • The segment-level analysis in terms of type and technology.
  • The value chain analysis, value that's created and captured by a company is the profit margin.Value
  • Created and Captured – Cost of Creating that Value = Margin
  • An executive summary consists of the whole report and the outcome is been given in the report to have brief knowledge about the report.
  • Basis on the depth of the study we approach using analytical tools
  • Expertise investment opportunities are given after analyzing the market to give the organization and the individual to have perfect knowledge about the market.


©2018 - Envision Inteligence | All Rights Reserved.